caa a22 4500 477120628 CHVBK 20180405111635.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00408661 doi (NATIONALLICENCE)springer-10.1007/BF00408661 Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade [Elektronische Daten] [Manfred Böhm, Andrea Lippoldt, Wolfgang Wienen, Detlev Ganten, Michael Bader] TGR(mREN2)27 is a transgenic rat harboring the murine Ren-2 gene and exhibit fulminant hypertension and marked heart hypertrophy. In order to study the role of angiotensin II in the increase of cardiac mass, these animals were treated with anti-hypertensive and non-antihypertensive doses of the angiotensin II receptor AT1 antagonist Telmisartan for 9 weeks. All doses led to significant reductions of heart hypertrophy detected by the evaluation of the diameter of cardiac muscle bundles. We conclude from this study that cardiac hypertrophy in TGR(mREN2)27 is characterized by an increased volume of cardiomyocytes and an unchanged amount of fibrous tissue and that angiotensin II plays an important role in the mechanisms leading to this phenotype. Kluwer Academic Publishers, 1996 heart hypertrophy nationallicence transgenic rats nationallicence hypertension nationallicence angiotensin II nationallicence Böhm Manfred Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut Lippoldt Andrea Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut Wienen Wolfgang A Pharma Research, Dr. Karl Thomae GmbH, Biberach, Germany aut Ganten Detlev Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut Bader Michael Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut Molecular and Cellular Biochemistry Kluwer Academic Publishers; http://www.wkap.nl 163-164/1(1996-03-01), 217-221 0300-8177 163-164:1<217 1996 163-164 11010 https://doi.org/10.1007/BF00408661 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00408661 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Böhm Manfred Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut NATIONALLICENCE 700 1- Lippoldt Andrea Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut NATIONALLICENCE 700 1- Wienen Wolfgang A Pharma Research, Dr. Karl Thomae GmbH, Biberach, Germany aut NATIONALLICENCE 700 1- Ganten Detlev Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut NATIONALLICENCE 700 1- Bader Michael Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buck aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Kluwer Academic Publishers; http://www.wkap.nl 163-164/1(1996-03-01), 217-221 0300-8177 163-164:1<217 1996 163-164 11010 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer